Mark D. Rosen
Janssen Pharmaceutica
24 Papers
190 Citations
Mark D. Rosen is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Total synthesis & Hypoxia-inducible factors. The author has an hindex of 14, co-authored 24 publications. Previous affiliations of Mark D. Rosen include Johnson & Johnson Pharmaceutical Research and Development & University of California, Irvine.
Chat about Author
Papers
Total Synthesis of (−)‐Spirotryprostatin B and Three Stereoisomers
Larry E. Overman,Mark D. Rosen +1 more
TL;DR: It is demonstrated that an acyclic, chiral η(3)-allylpalladium fragment generated in a catalytic asymmetric Heck cyclization can be trapped by even a weakly nucleophilic diketopiperazine more rapidly than it undergoes diastereomeric equilibration.
149
Total Synthesis of (+/-)-Didehydrostemofoline (Asparagamine A) and (+/-)-Isodidehydrostemofoline
Markus Brüggemann,Andrew I. McDonald,Larry E. Overman,Mark D. Rosen,Lothar Schwink,Jeremy P. Scott +5 more
TL;DR: The first total syntheses of (+/-)-didehydrostemofoline (1) and (+/--isodideHydrostem ofoline (3) are reported, which in 15 additional steps are converted to 1 and 3.
91
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor.
Terrance D. Barrett,Heather L. Palomino,Theresa I. Brondstetter,Kimon C. Kanelakis,Xiaodong Wu,Peter Haug,Wen Yan,Andrew A. Young,Hong Hua,Juliet C Hart,Da-Thao Tran,Hariharan Venkatesan,Mark D. Rosen,Hillary M Peltier,Kia Sepassi,Michele C. Rizzolio,Scott D. Bembenek,Tara Mirzadegan,Michael H. Rabinowitz,Nigel P. Shankley +19 more
TL;DR: The results demonstrate that JNJ-42041935 is a new pharmacological tool, which can be used to investigate PHD inhibition and demonstrate that PHD inhibitors offer great promise for the treatment of inflammation-induced anemia.
Prospective analysis of single operator sonographic optic nerve sheath diameter measurement for diagnosis of elevated intracranial pressure.
Erica Frumin,Joelle Schlang,Warren Wiechmann,Stacy Hata,Sasha Rosen,Craig L. Anderson,Laura Pare,Mark D. Rosen,John C. Fox +8 more
TL;DR: While the study suggests ONSD measurements performed by a single skilled operator may be both sensitive and specific for detecting eICP, confirmation in a much larger sample is needed.
Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues
Mark D. Rosen,Hariharan Venkatesan,Hillary M Peltier,Scott D. Bembenek,Kimon C. Kanelakis,Lucy X. Zhao,Barry Eastman Leonard,Frances M. Hocutt,Xiaodong Wu,Heather L. Palomino,Theresa I. Brondstetter,Peter V. Haugh,Laurence Cagnon,Wen Yan,Lisa A. Liotta,Andy Young,Tara Mirzadegan,Nigel P. Shankley,Terrance D. Barrett,Michael H. Rabinowitz +19 more
TL;DR: Certain benzimidazole-2-pyrazole carboxylates were discovered to be PHD2 inhibitors using ligand- and structure-based methods and found to be potent, orally efficacious stimulators of erythropoietin secretion in vivo.